Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
86.17 USD -0.27% Intraday chart for BioNTech SE -0.97% -18.35%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... Our Logo
Market outlook is uncertain, but optimism prevails Our Logo
BioNTech SE Announces Three-Year Follow-Up Data from Phase 1 Trial with the mRNA-Based Individualized Neoantigen-Specific Immunotherapy Candidate Autogene Cevumeran CI
BioNTech Reports Positive 3-Year Data From Phase 1 Trial of Cevumeran in Pancreatic Cancer MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher MT
UBS Cuts BioNTech Price Target to $101 From $110, Maintains Neutral Rating MT
News Highlights : Top Company News of the Day - Tuesday at 7 AM ET DJ
European Midday Briefing : Investors Hold Back Ahead of Key Inflation Print DJ
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET DJ
News Highlights : Top Company News of the Day - Tuesday at 3 AM ET DJ
BioNTech gets US agency notice over default on COVID vaccine royalties RE
Moderna, Inc. prepares for the post-Covid era Our Logo
BioNTech gets notice from US agency over default on COVID vaccine royalties RE
BioNTech gets notice from NIH on default on royalties RE
BioNTech SE Receives Notice of Default from the NIH CI
BIONTECH : Deutsche Bank remains Neutral ZD
TD Cowen Adjusts BioNTech Price Target to $95 From $101, Maintains Market Perform Rating MT
BIONTECH : A miss is a miss Alphavalue
BIONTECH : Deutsche Bank reaffirms its Neutral rating ZD
BIONTECH : Goldman Sachs reiterates its Neutral rating ZD
Wall St ends higher as Fed sees three rate cuts RE
BIONTECH : Jefferies sticks Neutral ZD
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sector Update: Health Care Stocks Down Wednesday Afternoon MT
Sector Update: Health Care MT
Chart BioNTech SE
More charts
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
80.81 EUR
Average target price
106.3 EUR
Spread / Average Target
+31.55%
Consensus
  1. Stock Market
  2. Equities
  3. BNTX Stock
  4. News BioNTech SE
  5. BioNTech Signs License, Investment Deals With Autolus Therapeutics